Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.
复制标题
ERA-EDTA注册中心的结果表明，欧洲透析患者和肾脏移植受者的Covid-19导致高死亡率。
DOI：
10.1016/j.kint.2020.09.006
复制
发表时间：
2020-12
影响因子：
19.6
通讯作者：
Massy ZA
中科院分区：
文献类型：
--
作者：
Jager KJ;Kramer A;Chesnaye NC;Couchoud C;Sánchez-Álvarez JE;Garneata L;Collart F;Hemmelder MH;Ambühl P;Kerschbaum J;Legeai C;Del Pino Y Pino MD;Mircescu G;Mazzoleni L;Hoekstra T;Winzeler R;Mayer G;Stel VS;Wanner C;Zoccali C;Massy ZA
本研究的目的是调查欧洲肾脏替代治疗人群中COVID-19诊断后28天的死亡率。此外，我们使用欧洲2020年2月1日至2020年4月30日接受肾脏替代治疗患者的ERA-EDTA登记数据，确定了患者特征、治疗因素和国家对死亡风险的作用。从7个欧洲国家收集了所有确诊为COVID-19的患者的额外数据，涉及4298名患者。使用倾向评分匹配的历史对照数据计算COVID-19可归因死亡率，随访28天后，3285名接受透析的患者的COVID-19可归因死亡率为20.0%（95%置信区间18.7%-21.4%），1013名接受移植的患者为19.9%（17.5%-22.5%）。我们发现了各国COVID-19死亡率的差异，以及接受肾脏替代治疗的老年患者和接受透析的男性患者的死亡风险增加。在年龄≥75岁的肾移植受者中，44.3%（35.7%-53.9%）的人未能在COVID-19中存活。移植受者的死亡风险是匹配透析患者的1.28（1.02-1.60）倍。因此，大流行病对接受肾脏替代疗法的患者的死亡率产生了重大影响，由于潜在的慢性肾脏疾病和多发性硬化症的高患病率，这是一个非常脆弱的人群。
The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompassing 4298 patients. COVID-19–attributable mortality was calculated using propensity score–matched historic control data and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%–21.4%) in 3285 patients receiving dialysis and 19.9% (17.5%–22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants ≥75 years of age, 44.3% (35.7%–53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02–1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy, a highly vulnerable population due to underlying chronic kidney disease and a high prevalence of multimorbidity.
登录
查看更多内容
影响因子：
13.6
作者：
Valeri, Anthony M.;Robbins-Juarez, Shelief Y.;Husain, S. Ali
通讯作者：
Husain, S. Ali
DOI：
10.2215/cjn.11331210
发表时间：
2011-07-01
影响因子：
9.8
作者：
Carrero, Juan J.;de Jager, Dinanda J.;Jager, Kitty J.
通讯作者：
Jager, Kitty J.
影响因子：
2.6
作者：
Emilio Sanchez-Alvarez, J.;Perez Fontan, Miguel;del Pino y Pino, Maria Dolores
通讯作者：
del Pino y Pino, Maria Dolores
影响因子：
13.2
作者：
Wang, Rui;Liao, Cong;Shui, Hua
通讯作者：
Shui, Hua
影响因子：
13.6
作者：
Mohan, Sumit
通讯作者：
Mohan, Sumit